INVO Fertility Adds Platelet-Rich Plasma Therapy Capabilities at Wisconsin Fertility Institute
INVO Fertility (Nasdaq: IVF) has announced the addition of Platelet-Rich Plasma (PRP) therapy to its fertility services at the Wisconsin Fertility Institute center. The treatment utilizes the body's own growth factors to stimulate uterine lining growth and ovarian rejuvenation, potentially improving implantation rates and ovarian response.
The therapy is specifically designed for women facing particular fertility challenges, including those with thin uterine lining, diminished ovarian reserve, and patients seeking alternatives before considering egg donation or surrogacy. Dr. Gretchen Collins, a double board certified OB/GYN and REI at Wisconsin Fertility Institute, notes that while PRP therapy remains experimental in fertility treatment, it has demonstrated success in other medical fields such as orthopedics and wound healing.
INVO Fertility (Nasdaq: IVF) ha annunciato l'introduzione della terapia con Plasma Ricco di Piastrine (PRP) tra i suoi servizi di fertilità presso il centro Wisconsin Fertility Institute. Questo trattamento sfrutta i fattori di crescita naturali del corpo per stimolare la crescita del rivestimento uterino e il ringiovanimento ovarico, con il potenziale di migliorare i tassi di impianto e la risposta ovarica.
La terapia è pensata specificamente per donne con particolari difficoltà di fertilità, come un endometrio sottile, riserva ovarica ridotta e per pazienti che cercano alternative prima di considerare la donazione di ovuli o la maternità surrogata. La dottoressa Gretchen Collins, specialista OB/GYN e REI con doppia certificazione presso il Wisconsin Fertility Institute, sottolinea che, sebbene la terapia PRP sia ancora sperimentale nel trattamento della fertilità, ha mostrato risultati positivi in altri ambiti medici come l'ortopedia e la guarigione delle ferite.
INVO Fertility (Nasdaq: IVF) ha anunciado la incorporación de la terapia con Plasma Rico en Plaquetas (PRP) a sus servicios de fertilidad en el centro Wisconsin Fertility Institute. Este tratamiento utiliza los factores de crecimiento naturales del cuerpo para estimular el crecimiento del revestimiento uterino y el rejuvenecimiento ovárico, lo que podría mejorar las tasas de implantación y la respuesta ovárica.
La terapia está diseñada específicamente para mujeres que enfrentan ciertos desafíos de fertilidad, incluyendo aquellas con un revestimiento uterino delgado, reserva ovárica disminuida y pacientes que buscan alternativas antes de considerar la donación de óvulos o la gestación subrogada. La doctora Gretchen Collins, ginecóloga certificada en OB/GYN y REI en Wisconsin Fertility Institute, señala que aunque la terapia PRP sigue siendo experimental en tratamientos de fertilidad, ha demostrado éxito en otras áreas médicas como la ortopedia y la cicatrización de heridas.
INVO Fertility (나스닥: IVF)가 위스콘신 생식 연구소 센터에서 혈소판 풍부 혈장(PRP) 치료를 생식 서비스에 추가했다고 발표했습니다. 이 치료법은 신체 고유의 성장 인자를 활용하여 자궁 내막 성장과 난소 재생을 촉진하며, 착상률과 난소 반응을 향상시킬 가능성이 있습니다.
이 치료는 얇은 자궁 내막, 감소된 난소 예비력, 그리고 난자 기증이나 대리모를 고려하기 전에 대안을 찾는 환자 등 특정 생식 문제를 겪는 여성들을 위해 설계되었습니다. 위스콘신 생식 연구소의 이중 전문 인증을 받은 산부인과 및 생식내분비 전문의인 그레첸 콜린스 박사는 PRP 치료가 생식 치료에서는 아직 실험 단계이지만, 정형외과 및 상처 치유와 같은 다른 의학 분야에서는 성공을 거두었다고 언급했습니다.
INVO Fertility (Nasdaq : IVF) a annoncé l'ajout de la thérapie par plasma riche en plaquettes (PRP) à ses services de fertilité au centre Wisconsin Fertility Institute. Ce traitement utilise les facteurs de croissance naturels du corps pour stimuler la croissance de la muqueuse utérine et le rajeunissement ovarien, ce qui pourrait améliorer les taux d'implantation et la réponse ovarienne.
Cette thérapie est spécialement conçue pour les femmes rencontrant des difficultés particulières en matière de fertilité, notamment celles ayant une muqueuse utérine fine, une réserve ovarienne diminuée, ainsi que pour les patientes recherchant des alternatives avant d'envisager un don d'ovocytes ou une gestation pour autrui. La Dre Gretchen Collins, gynécologue-obstétricienne et endocrinologue de la reproduction doublement certifiée au Wisconsin Fertility Institute, souligne que bien que la thérapie PRP soit encore expérimentale dans le traitement de la fertilité, elle a montré des résultats positifs dans d'autres domaines médicaux tels que l'orthopédie et la cicatrisation des plaies.
INVO Fertility (Nasdaq: IVF) hat die Aufnahme der Platelet-Rich Plasma (PRP) Therapie in sein Angebot an Fruchtbarkeitsdiensten im Wisconsin Fertility Institute bekannt gegeben. Die Behandlung nutzt körpereigene Wachstumsfaktoren, um das Wachstum der Gebärmutterschleimhaut und die Erneuerung der Eierstöcke zu fördern, was potenziell die Einnistungsraten und die ovarielle Reaktion verbessert.
Die Therapie richtet sich speziell an Frauen mit bestimmten Fruchtbarkeitsproblemen, darunter dünne Gebärmutterschleimhaut, verminderte ovarielle Reserve und Patientinnen, die Alternativen suchen, bevor sie eine Eizellspende oder Leihmutterschaft in Betracht ziehen. Dr. Gretchen Collins, doppelt zertifizierte Gynäkologin und Reproduktionsendokrinologin am Wisconsin Fertility Institute, weist darauf hin, dass die PRP-Therapie zwar noch experimentell in der Fruchtbarkeitsbehandlung ist, aber in anderen medizinischen Bereichen wie der Orthopädie und Wundheilung Erfolge gezeigt hat.
- Introduction of new innovative PRP therapy treatment option
- Minimally invasive approach using patient's own biological resources
- Potential alternative before pursuing more complex options like egg donation or surrogacy
- Treatment addresses multiple fertility challenges including thin uterine lining and diminished ovarian reserve
- PRP therapy is still considered experimental in fertility treatment
- Clinical effectiveness in fertility applications still being studied
Insights
INVO adds experimental PRP therapy at Wisconsin clinic; potentially broadens treatment options but clinical effectiveness still being studied.
INVO Fertility's introduction of Platelet-Rich Plasma (PRP) therapy at their Wisconsin center represents a calculated expansion into emerging fertility technologies. PRP therapy – which utilizes a patient's own growth factors to potentially stimulate uterine lining development and ovarian function – targets specific fertility challenges including thin endometrial lining and diminished ovarian reserve.
The clinical positioning here is notably measured. Dr. Collins explicitly characterizes PRP as "experimental but promising" in reproductive applications, while acknowledging its established benefits in orthopedics and wound healing. This transparency regarding its investigational status in fertility demonstrates appropriate clinical caution.
From a treatment perspective, PRP occupies a strategic middle ground in the fertility care spectrum – offering an additional option before patients progress to more involved procedures like egg donation or surrogacy. This positions INVO to potentially retain patients who might otherwise seek alternatives elsewhere.
The single-location implementation suggests a deliberate pilot approach rather than a comprehensive rollout. While this limits immediate market impact, it allows for experience-building with the technique before wider deployment.
This addition complements INVO's existing offerings and aligns with growing patient preference for treatments utilizing the body's own resources. However, without established efficacy data specific to fertility outcomes, its clinical and financial impact remains uncertain. The careful framing as an "additional option" rather than a breakthrough appropriately manages expectations while expanding INVO's treatment portfolio.
MIDDLETON, Wis. and SARASOTA, Fla., June 30, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare company focused on the fertility market, is excited to announce the addition of Platelet-Rich Plasma (PRP) therapy to its comprehensive suite of fertility services at its Wisconsin Fertility Institute center. This cutting-edge treatment offers additional options for individuals and couples facing fertility challenges, further expanding the center’s commitment to innovative, patient-centered care.
PRP is a cutting-edge treatment that uses your body's own growth factors to stimulate uterine lining growth and ovarian rejuvenation, potentially improving implantation rates and ovarian response. PRP therapy is particularly beneficial for women facing specific fertility challenges, including patients with a thin uterine lining; women with diminished ovarian reserve; and those looking to boost their chances of conception. The therapy is ideal for patients seeking alternatives before resorting to options like egg donation or surrogacy, offering a minimally invasive approach using the body’s own resources.
“PRP therapy represents another potentially helpful option in fertility care,” said Steve Shum, CEO of INVO Fertility. “By harnessing the body’s natural healing potential, our team at Wisconsin Fertility Institute is offering new possibilities for patients who may have felt their options were limited. We’re thrilled to bring this innovative treatment to the Wisconsin community.”
Dr. Gretchen Collins, at Wisconsin Fertility Institute, added, “As a double board certified OB/GYN and REI, I understand how deeply challenging fertility struggles can be. Platelet-Rich Plasma (PRP) therapy is an experimental but promising option in reproductive medicine. While its use in fertility is still being studied, PRP has shown value in other areas of medicine—such as orthopedics and wound healing—by supporting tissue repair and regeneration. We're hopeful that similar benefits may extend to ovarian and endometrial health, offering new hope to patients with minimal risk.”
Patients interested in exploring PRP therapy are encouraged to schedule a consultation with Wisconsin Fertility Institute’s team of experienced fertility specialists by visiting https://wisconsinfertility.com/ or at 608-824-0075.
About INVO Fertility
We are a healthcare fertility company dedicated to expanding assisted reproductive technology (“ART”) care to patients in need. Our principal commercial strategy is focused on building, acquiring and operating fertility clinics, including “INVO Centers” dedicated primarily to offering the intravaginal culture (“IVC”) procedure enabled by our INVOcell® medical device (“INVOcell”) and US-based, profitable in vitro fertilization (“IVF”) clinics. We have two operational INVO Centers in the United States and one IVF clinic. We also continue to engage in the sale and distribution of our INVOcell technology solution into third-party owned and operated fertility clinics. The INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body. The IVC procedure provides patients with a more natural, intimate, and affordable experience in comparison to other ART treatments. We believe the IVC procedure can deliver comparable results at a fraction of the cost of traditional IVF and is a significantly more effective treatment than intrauterine insemination (“IUI”). For more information, please visit www.invofertility.com.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
For more information, please contact:
INVO Fertility, Inc.
Steve Shum, CEO
978-878-9505
sshum@invobio.com
Investor Contact
Lytham Partners, LLC
Robert Blum
602-889-9700
INVO@lythampartners.com
FAQ
What is PRP therapy at INVO Fertility's Wisconsin Fertility Institute?
Who can benefit from INVO Fertility's PRP therapy treatment?
Is PRP therapy at INVO Fertility (IVF) proven effective for fertility treatment?
How can patients access PRP therapy at Wisconsin Fertility Institute?
What makes INVO Fertility's PRP therapy different from other fertility treatments?
